Project Details
Description
A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared o Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients
| Status | Finished |
|---|---|
| Effective start/end date | 7/22/10 → 4/30/17 |
Funding
- MERCK AND CO INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.